Discover the clinical significance of Lipoprotein(a) screening and testing with Dr. Keith Ferdinand! Dive into compelling insights as Dr. Ferdinand breaks down Lp(a) values for practical use in patient care and why highrisk priority populations are ever so important with the worsening disparities in US Life Expectancy. Unlock invaluable clinical perspectives on both. You won’t want to miss this!

Chapters
Welcome: 00:00 – 00:37

Speaker Introduction: 00:38 – 02:05

Disclosure: 02:07 – 02:16

Disclaimer: 02:19 02:37

Learning Objectives: 02:43 – 03:21

Case Study: 03:23 – 07:11

Lp(a): Atherogenic LDLlike Lipoprotein: 07:19 – 08:19

Lp(a): Independent, Causal, Genetic CVD Risk Factor: 08:20 – 09:18

Plasma Lp(a) Follows a Skewed Distribution: 09:21 – 10:17

Independent and Joint Association of Lipoprotein(a) and Family History with Cardiovascular Risk: 10:21 – 10:55

How Lp(a) is Measured: 11:01 – 11:38

Coding: 11:42 – 11:57

Lp(a) Levels Predominantly Genetically Determined: 12:03 – 13:28

NHLBI Working Group: Regions of Ancestry: 13:32 – 14:24

Lp(a) Metabolism: 14:28 – 15:59

Conclusive Evidence: 16:04 – 16:48

Lp(a) in Special Populations: 16:52 – 22:17

Lipoprotein(a) and LongTerm Incidence of ASCVD: 22:21 – 24:27

Putting Lp(a) Data into Practice and NLA Updates: 24:32 – 32:39

What We Know Now and What Will the Future Hold: 32:42 – 35:17

Patient Information and Education: 35:25 – 40:26

Take Home Messages: 40:28 – 42:18

Q&A: 42:20 – 59:14

Closing: 59:18 – 1:00:03